SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2175416579> ?p ?o ?g. }

Showing items 1 to 100 of ±199 with 100 items per page.

W2175416579 endingPage "2416" @default.
W2175416579 startingPage "2401" @default.
W2175416579 abstract "Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of concurrent MYC and BCL6 translocations is not well known. In this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 in 898 patients with de novo diffuse large B-cell lymphoma treated with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). Neither BCL6 translocation alone (more frequent in activated B-cell like diffuse large B-cell lymphoma) nor in combination with MYC translocation (observed in 2.0% of diffuse large B-cell lymphoma) predicted poorer survival in diffuse large B-cell lymphoma patients. Diffuse large B-cell lymphoma patients with MYC/BCL6 co-expression did have significantly poorer survival, however, MYC/BCL6 co-expression had no effect on prognosis in the absence of MYC/BCL2 co-expression, and had no additive impact in MYC+/BCL2+ cases. The isolated MYC+/BCL6+/BCL2- subset, more frequent in germinal center B-cell like diffuse large B-cell lymphoma, had significantly better survival compared with the isolated MYC+/BCL2+/BCL6- subset (more frequent in activated B-cell like diffuse large B-cell lymphoma). In summary, diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis; MYC expression levels should be evaluated simultaneously; and double-hit B-cell lymphoma needs to be refined based on the specific genetic abnormalities present in these tumors." @default.
W2175416579 created "2016-06-24" @default.
W2175416579 creator A5000027373 @default.
W2175416579 creator A5003670546 @default.
W2175416579 creator A5004565426 @default.
W2175416579 creator A5007853425 @default.
W2175416579 creator A5008975834 @default.
W2175416579 creator A5010675319 @default.
W2175416579 creator A5013543100 @default.
W2175416579 creator A5014966517 @default.
W2175416579 creator A5016760892 @default.
W2175416579 creator A5018907621 @default.
W2175416579 creator A5018999020 @default.
W2175416579 creator A5021486539 @default.
W2175416579 creator A5022967729 @default.
W2175416579 creator A5027080346 @default.
W2175416579 creator A5031480761 @default.
W2175416579 creator A5032347848 @default.
W2175416579 creator A5037453366 @default.
W2175416579 creator A5041293621 @default.
W2175416579 creator A5041326568 @default.
W2175416579 creator A5054381821 @default.
W2175416579 creator A5057884333 @default.
W2175416579 creator A5064786948 @default.
W2175416579 creator A5065041295 @default.
W2175416579 creator A5066716873 @default.
W2175416579 creator A5074244429 @default.
W2175416579 creator A5077756892 @default.
W2175416579 creator A5085410438 @default.
W2175416579 creator A5089689144 @default.
W2175416579 date "2015-11-12" @default.
W2175416579 modified "2023-10-18" @default.
W2175416579 title "Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma" @default.
W2175416579 cites W1493375167 @default.
W2175416579 cites W1502170811 @default.
W2175416579 cites W1590112381 @default.
W2175416579 cites W1945538340 @default.
W2175416579 cites W1949227380 @default.
W2175416579 cites W1956719435 @default.
W2175416579 cites W1965527127 @default.
W2175416579 cites W1970739365 @default.
W2175416579 cites W1971894480 @default.
W2175416579 cites W1978932947 @default.
W2175416579 cites W1982834279 @default.
W2175416579 cites W2004916962 @default.
W2175416579 cites W2006070956 @default.
W2175416579 cites W2007050465 @default.
W2175416579 cites W2009002059 @default.
W2175416579 cites W2019135859 @default.
W2175416579 cites W2026214119 @default.
W2175416579 cites W2028850684 @default.
W2175416579 cites W2034060278 @default.
W2175416579 cites W2035611379 @default.
W2175416579 cites W2037217230 @default.
W2175416579 cites W2037904581 @default.
W2175416579 cites W2043622833 @default.
W2175416579 cites W2056555760 @default.
W2175416579 cites W2056641238 @default.
W2175416579 cites W2057239580 @default.
W2175416579 cites W2064223130 @default.
W2175416579 cites W2066358008 @default.
W2175416579 cites W2091130540 @default.
W2175416579 cites W2096596684 @default.
W2175416579 cites W2097202399 @default.
W2175416579 cites W2100197564 @default.
W2175416579 cites W2113878188 @default.
W2175416579 cites W2116956926 @default.
W2175416579 cites W2120415962 @default.
W2175416579 cites W2128710750 @default.
W2175416579 cites W2137216850 @default.
W2175416579 cites W2137807267 @default.
W2175416579 cites W2140065103 @default.
W2175416579 cites W2144311569 @default.
W2175416579 cites W2147246240 @default.
W2175416579 cites W2148654292 @default.
W2175416579 cites W2150729931 @default.
W2175416579 cites W2151443313 @default.
W2175416579 cites W2153422981 @default.
W2175416579 cites W2153944703 @default.
W2175416579 cites W2159862107 @default.
W2175416579 cites W2160848167 @default.
W2175416579 cites W2162212325 @default.
W2175416579 cites W2169948694 @default.
W2175416579 cites W2172230584 @default.
W2175416579 cites W2263869806 @default.
W2175416579 doi "https://doi.org/10.18632/oncotarget.6262" @default.
W2175416579 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4823044" @default.
W2175416579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26573234" @default.
W2175416579 hasPublicationYear "2015" @default.
W2175416579 type Work @default.
W2175416579 sameAs 2175416579 @default.
W2175416579 citedByCount "83" @default.
W2175416579 countsByYear W21754165792016 @default.
W2175416579 countsByYear W21754165792017 @default.
W2175416579 countsByYear W21754165792018 @default.
W2175416579 countsByYear W21754165792019 @default.
W2175416579 countsByYear W21754165792020 @default.
W2175416579 countsByYear W21754165792021 @default.